Sanuwave (SNWV) Q4 2025 Earnings Transcript

SANUWAVE reported record Q4 revenue of $13.4 million, up 30% year over year, and full-year revenue of $44.1 million, up 35%, with adjusted EBITDA rising to $4.8 million in Q4 and $13.6 million for the year. Gross margin was 74.7% in Q4, down 320 bps due to a $486,000 PACE inventory write-off, while guidance calls for Q1 2026 revenue of $9.6 million to $10.3 million and preliminary full-year growth of 16% to 25%. Management flagged meaningful customer disruption from CMS reimbursement changes, but also highlighted stronger reseller/channel traction and improving inbound demand.

Analysis

The key read-through is that SNWV is trying to convert a reimbursement shock into a channel-reset opportunity. The wholesale/reseller pivot should improve operating leverage if channel inventory stays contained, but it also creates a near-term visibility problem: reported shipments can outrun end-user demand, so the market may be forced to discount headline growth until active-system data proves the base is stabilizing. That makes the next 1-2 quarters more about channel health and customer survivability than revenue acceleration alone.

The bigger second-order effect is competitive. CMS pressure is not just hurting SNWV’s customers; it is forcing a reshuffle of practitioner economics, which should favor treatments that are easier to justify, faster to deploy, and less administratively exposed. That is a structural tailwind for UltraMIST if management can convert displaced practices and new “baby elephant” entrants before competitors rearm, but it also means a prolonged sales-cycle reset in hospitals/IDNs where adoption lags.

A contrarian issue the market may be missing is that the apparent margin expansion can be partially optical if channel mix keeps shifting toward stocking distributors. Wholesale ASP compression and lower sales-force burden can look great in EBITDA while obscuring weaker end-demand or future inventory normalization. The key upside catalyst is a clean Q1/Q2 showing that active systems and consumables per active system are inflecting higher despite the CMS hangover; the key downside catalyst is a wave of further customer closures or inventory destocking that would force another reset in guidance.

Key Decisions for Investors

• Tactically long SNWV only on pullbacks or post-Q1 confirmation, sized small: upside is a multiple re-rate if active-system growth re-accelerates, but downside is high if the channel is front-loading shipments and end-demand weakens.
• Sell downside protection / buy calls on SNWV into Q1 print: consider a 1-2 month call spread to express a rebound in sentiment if management proves the “shock bottom” narrative, while capping premium at risk.
• Pair trade: long SNWV / short a basket of reimbursement-exposed wound-care or skin-substitute proxies over 3-6 months, betting CMS pressure creates share shift toward simpler therapies; keep tight stop if audit pressure eases faster than expected.
• Avoid chasing the name solely on reported revenue growth until active systems and consumables velocity are disclosed for 1-2 more quarters; the cleaner entry is after evidence of post-disruption cohort retention.
• Watch for a short-term squeeze if guidance is revised up at Q1/Q2: any confirmation that the reseller channel is not causing inventory overhang could force a sharp multiple expansion, but if active counts stall, the stock likely retraces quickly.